Beckman Coulter is in the forefront of bringing novel biomarkers and new clinical solutions to advance patient care. The Prostate Health Index (phi) test includes assessment of a novel biomarker p2PSA, an isoform of free PSA. Beckman Coulter aims to showcase the value of phi as an aid in distinguishing prostate cancer from benign prostatic conditions and for prostate cancer detection in men aged 50 years and older with total prostate-specific antigen (tPSA) between 4-10ng/mL and with digital rectal examination (DRE) findings that are not suspicious for cancer or men with no prior biopsy as well men with prior negative biopsy. Prostate Health Index (phi) test is proprietary to Beckman Coulter.